Innovative Formulations in Pharmacology: From Nanoemulsions to Controlled Drug Delivery

Chandni Rai[1], Ekta Mishra[2], Dipak Sariya[3], Niharika Thakur[4]

[1.] *Research Scholar, School of Pharmacy, LNCT University, Kolar road Bhopal, India*
[2.] *Student, Sant Hirdaram Girls College, Bhopal*
[3.] *Student, Sam College of Pharmacy, Sam University, Bhopal, India*
[4.] *Senior Research Associate, Pinnacle Biomedical Research Institute, Bhopal*

Corresponding author: Dr. Niharika Thakur
Email: niharika87thakur@gmail.com
Doi: **10.5281/zenodo.17102007**
Received: 25 July 2025
Accepted: 12 August 2025

Abstract
Preclinical toxicology plays a pivotal role in the safety evaluation of novel therapeutic agents. The evolving landscape of toxicological assessments necessitates integration between in vitro, in vivo, and translational approaches. This review outlines key advancements in preclinical toxicology, focusing on emerging technologies such as organ-on-a-chip systems, improved animal models, and computational toxicology and overview of innovative formulations in pharmacology, focusing on nanoscale drug delivery systems, novel drug delivery technologies, and future directions in drug formulation.. The article also discusses key technologies like high-pressure homogenization, nanoemulsions, and supercritical fluid techniques have significantly advanced the field, enabling the creation of stable and effective formualtion and also translational challenges and regulatory perspectives, aiming to provide a comprehensive understanding of how modern strategies are bridging gaps between laboratory studies and clinical safety.

1. Introduction

1.1Techniques involve for the development and production of nanoscale drug formulation

Fundamentally, there are two different approaches for creating nanoscale formulations: top-down and bottom-up. Chemical processes and molecular assemblies, including spray-drying, polymerization, synthesis, nanoemulsion, precipitation, and supercritical fluid procedures, are examples of bottom-up methods. Wet media milling and high-pressure homogenization are examples of top-down methods. Nanosuspensions are the term used to describe the resultant nanoparticles**(Van et al., 2007).**



Figure 1 : Advancement in the drug delivery system

Stabilized submicron colloidal dispersions of drug particles at the nanoscale are called nanosuspensions 30 Nanosuspensions have been developed and produced using a variety of technologies. Regarding top-down tactics, high-pressure homogenization is a crucial method. A piston-gas homogenizer was used to create the first high pressure homogenization technique, which was then processed in room temperature aqueous media,**(Müller& Peters1998)**and later in non-aqueous media (patent number: WO2001003670, 2001). J. Kluge and M. Mazzotticreated S-ketoprofen poly(lactic-co-glycolic acid) (PLGA) drug-polymer nanocomposites with high pressure homogenization aided by CO2, which significantly increased the drug's bioavailability(**Kluge&Mazzotti et al., 2012).** Pereda et al. found that after treatment by high- pressure homogenization, the storage of milk fat was significantly improved.

Other types of high-pressure homogenization, such as media milling**(Van et al., 2007)**and Nanoedge (US Patent 6018080, 2000), were also involved in the production of nanoscale drug formulations. Several pharmaceutical companies have developed a certain kind of processing standard operating procedures (SOPs) based on high pressure homogenization techniques, for example the Nanomorph™ from Abbott. Elan Nano-systems' NanocrystalTM and Baxter's Nanoedge. Wet ball milling is another crucial technique used in the industry to lower particle size. More than five nanoscale medication formulations made using this technique are currently available on the market, while several more are still in the research and development phase.

Interestingly, all FDA-approved top-down strategy nanoscale medication formulations are intended for oral administration.

Regarding the bottom-up approach, the creation of nanoemulsions is a potent technique in addition to traditional synthesis and polymerization. Since a nanoemulsion is a medication in and of itself, it can be used as a model to create nanosuspensions **(Van et al., 2008).** Solid-lipid and polymeric nanoparticles are most frequently prepared using the solvent emulsification diffusion (SED) technique**(Mishra et al., 2010).**Thousands of medications and active pharmaceutical ingredients (APIs) have been thoroughly studied and produced due to the ease and convenience of creating nanoemulsions, which can precisely control drug loading and positioning (spatial placement). For instance, the market presently offers ibuprofen, diclofenac, and acyclovir nanosuspensions

In the early 2000s, the pharmaceutical sector and literature both paid close attention to supercritical fluid techniques, which are also significant.38,39 One popular supercritical fluid is SC (supercritical)-CO2. The ability of CO2 to function as a low-density solvent above its supercritical point was created to boost the manufacturing of nanoparticles from the lab to the pilot scale. Rapid expansion of supercritical solution (RESS) is one of the most widely used supercritical fluid procedures. RESS can produce nanoparticles with diameter less than 100 nm41 and free of solvents, which is quite promising for the fabrication of nanosuspensions. The combination of a supercritical fluid with an emulsion process offers greater benefit than the use of a single technique alone. For example, Porta et al. produced PLGA polymers loaded with 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) by using supercritical CO2 fluid to extract drug molecules from the oily phase of an emulsion.

1.1 Novel Drug Delivery Systems for Enhanced Patient Compliance

One of the biggest challenges in healthcare is achieving and sustaining patient compliance, and drug delivery systems are essential to solving this problem. By offering practical, efficient, and easy-to-use ways to dispense drugs, innovative drug delivery systems have been created to improve patient compliance. These solutions increase the whole patient experience in addition to improving treatment outcomes.

1.1.1 Controlled-Release Drug Delivery Systems:

Controlled-release systems, pioneered by researchers like Robinson **(Robinson et al., 1987),** provide long-term, consistent medication release. This makes it easier for patients to follow their prescription schedules by lowering the frequency of doses and minimizing negative effects.

1.1.2 Transdermal Drug Delivery

Transdermal patches, such as the work by Prausnitz**(Prausnitz et al., 2004)**, permit medication absorption via the skin. Particularly for chronic illnesses, these patches offer a continuous, painless, and simple delivery strategy that can increase patient compliance.

1.1.3 Implantable Drug Delivery Devices

Implantable devices, like those researched by Anderson **(Anderson et al., 1997),**provide long- term medication administration. Adherence to treatment plans is improved because patients receive regulated dosages without the need for frequent administration.

1.1.4 Inhalation Drug Delivery

Metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are two examples of inhalation devices that provide tailored administration to the respiratory system. Researchers like Lavorini**(Lavorini, 2019)** have contributed to the development of these systems, making them an effective choice for treating respiratory conditions while improving patient compliance.

1.1.5 Oral Drug Delivery Technologies

By offering convenient and simple-to-administer options, innovative oral drug delivery technologies including oral disintegrating tablets (ODTs) and nanoparticles improve patient compliance. Researchers like Rao **(Velmuruganet al., 2010)** have advanced these technologies.

1.1.6 Personalized Medicine

Tailored drug delivery systems, supported by research in pharmacogenomics **(Hamburg and Collins, 2010),**strive to align medication formulations with a person's genetic composition. Personalized medicine can improve patient adherence by minimizing side effects and increasing therapeutic efficacy.

1.1.7 Smart Drug Delivery Systems

Researchers like Farokhzad**(Farokhzad et al., 2014)** have invented intelligent medication delivery methods that react to physiological signals. These systems provide accurate and patient- friendly treatment by releasing medications in response to particular bodily circumstances.

1.2 Future Directions in Drug Formulation Technology

Drug formulation technology is a dynamic and ever-evolving discipline. We must take into account new trends, developments in technology, and healthcare requirements in order to predict its future paths. The future of drug formulation technology is expected to be shaped by a number of exciting topics:

A. Nanomedicine.

Drug delivery systems are predicted to undergo a revolution thanks to nanotechnology. In order to improve drug solubility, increase bioavailability, and accurately target illness locations, researchers are creating nanoparticles, nanocarriers, and nanoscale drug formulations. These developments could revolutionize gene delivery, customized medicine, and cancer treatment. **(Davis et al., 2018).**

B. 3D Printing

In the pharmaceutical industry, three-dimensional (3D) printing technology is becoming more popular. It makes it possible to create customized, patient-specific therapeutic dosage forms that provide improved drug release patterns and accurate dosing. 3D printing also streamlines the manufacturing process, potentially reducing costs and increasing accessibility to tailored medications **(Sadia et al., 2019).**

C. Artificial Intelligence (AI) and Machine Learning

AI and machine learning are being used to find new excipients, forecast stability problems, and improve medicine formulations. These technologies have the potential to greatly speed up formulation development, increasing its effectiveness and economy. AI and machine learning are being used to find new excipients, forecast stability problems, and improve medicine formulations. These technologies have the potential to greatly speed up formulation development, increasing its effectiveness and economy. **(Chaudhari et al., 2020)**

D. Drug-Device Combinations

There is an increasing trend of combining pharmaceutical formulations with drug delivery devices. Wearable patches, networked medication delivery devices, and smart inhalers are being developed to increase patient adherence, track treatment outcomes, and give medical professionals real-time data**(Radosavljevicet al., 2023).**

E. Sustainable and Green Formulations

As environmental concerns grow, there is a shift toward developing eco-friendly formulations. Green chemistry principles are being applied to reduce the environmental impact of pharmaceutical manufacturing, including the use of sustainable solvents and reducing waste **(Constable et al., 200)**

2. In Vitro Toxicology: Evolution and Innovations The evolution of in vitro toxicology has been marked by a shift from simple cell culture assays to complex 3D cell cultures and organ-on- a-chip models. These systems offer improved physiological relevance and enable the study of organ-specific toxicity. High-throughput screening (HTS) and high-content imaging (HCI) have further accelerated toxicity profiling, allowing rapid and detailed analysis of compound effects. Despite these advances, challenges remain, including limited metabolic competence and inability to fully replicate in vivo environments.

3. In Vivo Toxicology: Refinement and Ethical Considerations Animal models remain integral to toxicological evaluation, offering insights into systemic and long-term effects. However, ethical concerns and regulatory pressures have led to significant refinements. The adoption of the 3Rs principle (Replacement, Reduction, Refinement) has driven the development of more humane and efficient models. Genetically modified organisms and alternative species like zebrafish are being increasingly employed. Advanced imaging techniques and non-invasive biomarkers now provide deeper insights while minimizing animal suffering.

4. Translational Toxicology: Bridging Laboratory and Clinic Translational toxicology seeks to correlate preclinical findings with clinical outcomes, thus enhancing the predictability of safety assessments. Biomarker discovery, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and case-based examples (e.g., drug-induced liver injury) illustrate successful translation. These efforts rely on cross-disciplinary collaboration and continuous feedback between bench and bedside.

5. Integrative Approaches and Computational Toxicology Computational tools are increasingly utilized to predict toxicological outcomes. Quantitative structure-activity relationships (QSAR), physiologically based pharmacokinetic (PBPK) models, and systems toxicology enable data integration across experimental platforms. Artificial intelligence (AI) and machine learning algorithms further enhance predictive accuracy by analyzing large and complex datasets. These in silico methods are valuable for hypothesis generation, risk assessment, and reducing reliance on animal studies.

6. Regulatory Perspectives and Global Harmonization Regulatory bodies such as the FDA, EMA, and OECD play a crucial role in defining acceptable preclinical safety standards. The implementation of ICH guidelines and adherence to Good Laboratory Practices (GLP) ensure the quality and reliability of toxicological data. There is a global push towards harmonization and acceptance of alternative methods, including the use of validated in vitro models and computational approaches in regulatory submissions.

7. Challenges and Future Directions Despite remarkable progress, several challenges persist. These include limited concordance between preclinical and clinical data, species-specific responses, and the need for more comprehensive human-relevant models. Future directions involve integrating omics technologies, enhancing personalized toxicology, and developing interconnected multi-organ chips. Collaborative, interdisciplinary approaches are essential to realize the full potential of modern toxicology.

8. Conclusion Preclinical toxicology is undergoing a transformative phase, marked by technological innovation and a shift towards integrative, predictive, and ethical models. Bridging the gaps between in vitro assays, in vivo studies, and clinical relevance is critical for advancing drug safety. The integration of novel drug delivery technologies, such as controlled-release systems, transdermal patches, implantable devices, and inhalation delivery, has greatly enhanced patient compliance and treatment outcomes. Looking forward, the convergence of nanomedicine, 3D printing, artificial intelligence, drug-device combinations, and sustainable formulations holds immense promise for the future of pharmacology. Continued progress will depend on regulatory support, technological integration, and collaborative efforts across scientific domains.

9. References

1. Van Eerdenbrugh, B., Froyen, L., Martens, J. A., Blaton, N., Augustijns, P., Brewster, M., & Van den Mooter, G. (2007). Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze–dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. *International journal of pharmaceutics*, *338*(1-2), 198-206.
2. Kluge, J., &Mazzotti, M. (2012). CO2-assisted high pressure homogenization: A solvent-free process for polymeric microspheres and drug–polymer composites. *International journal of pharmaceutics*, *436*(1-2), 394-402.
3. Müller, R. H., & Peters, K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. *International journal of pharmaceutics*, *160*(2), 229-237.
4. Van Eerdenbrugh, B., Froyen, L., Martens, J. A., Blaton, N., Augustijns, P., Brewster, M., & Van den Mooter, G. (2007). Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze–dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. *International journal of pharmaceutics*, *338*(1-2), 198-206.
5. Sheen, P. C., Kim, S. I., Petillo, J. J., &Serajuddin, A. T. (1991). Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. *Journal of Pharmaceutical Sciences*, *80*(7), 712-714.
6. Van Eerdenbrugh, B., Van den Mooter, G., &Augustijns, P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. *International journal of pharmaceutics*, *364*(1), 64-75.
7. Mishra, B. B. T. S., Patel, B. B., & Tiwari, S. (2010). Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. *Nanomedicine: Nanotechnology, biology and medicine*, *6*(1), 9-24.
8. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS nano*, *3*(1), 16-20.
9. Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. *New England Journal of Medicine*, *363*(4), 301-304.
10. Velmurugan, S., &Vinushitha, S. (2010). Oral disintegrating tablets: An

overview. *International Journal of Chemical and Pharmaceutical Sciences*, *1*(2), 1-12.

11. Lavorini, F. (2014). Inhaled drug delivery in the hands of the patient. *Journal of aerosol medicine and pulmonary drug delivery*, *27*(6), 414-418.
12. Anderson, J. M., & Shive, M. S. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. *Advanced drug delivery reviews*, *28*(1), 5-24.
13. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature biotechnology*, *26*(11), 1261-1268.
14. Robinson, J., & Lee, V. H. (1987). *Controlled drug delivery: fundamentals and applications*. CRC Press.
15. Porter, C. J., Trevaskis, N. L., &Charman, W. N. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. *Nature reviews Drug discovery*, *6*(3), 231-248.
16. Radosavljevic, M., SvobStrac, D., Jancic, J., &Samardzic, J. (2023). The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. *Genes*, *14*(5), 1095.